Apellis Pharmaceuticals, Inc. (APLS) Tops Q2 EPS by 34c
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Join SI Premium – FREE
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.02), $0.34 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $95 million versus the consensus estimate of $70.24 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nebius soars on second quarter revenue beat
- LiqTech International (LIQT) Reports In-Line Q2 EPS
- WhiteFiber, Inc. (WYFI) Misses Q2 EPS by 36c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
